Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19004820 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Kim I, et al. (2009) Chemical biology investigation of cell death pathways activated by endoplasmic reticulum stress reveals cytoprotective modulators of ASK1. J Biol Chem 284, 1593-603 19004820
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S83-p - ASK1 (human) ▲
Orthologous residues
ASK1 (human): S83‑p, ASK1 iso5 (human): S163‑p, ASK1 (mouse): S90‑p, ASK1 (rat): S54‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioma, ovarian cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), OVCAR5 (ovarian), SNB-19 (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  CSM14.1 rat straital neuroprogenitor cell line
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease benzodiazepinones
increase benzodiazepinones

T838-p - ASK1 (human) ▲
Orthologous residues
ASK1 (human): T838‑p, ASK1 iso5 (human): T918‑p, ASK1 (mouse): T845‑p, ASK1 (rat): T809‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioma, ovarian cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), OVCAR5 (ovarian), SNB-19 (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  CSM14.1 rat straital neuroprogenitor cell line
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase benzodiazepinones

S966-p - ASK1 (human) ▲
Orthologous residues
ASK1 (human): S966‑p, ASK1 iso5 (human): S1046‑p, ASK1 (mouse): S973‑p, ASK1 (rat): S930‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioma, ovarian cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), OVCAR5 (ovarian), SNB-19 (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  CSM14.1 rat straital neuroprogenitor cell line
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
increase benzodiazepinones
increase active- CID 2891837
no change compared to control inactive- CID 2882293
thapsigargin augment treatment-induced increase
thapsigargin no change compared to control
Downstream Regulation
 Effect of modification (function):  enzymatic activity, inhibited, molecular association, regulation
 Effect of modification (process):  apoptosis, induced
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
14-3-3 beta (human) Induces co-immunoprecipitation
 Comments:  induced by CID-2891837

S52-p - eIF2-alpha (rat) ▲
Orthologous residues
eIF2‑alpha (human): S52‑p, eIF2‑alpha (mouse): S52‑p, eIF2‑alpha (rat): S52‑p, eIF2‑alpha (rabbit): S51‑p, eIF2‑alpha (fruit fly): S51‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioma, ovarian cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), OVCAR5 (ovarian), SNB-19 (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  CSM14.1 rat straital neuroprogenitor cell line

S73-p - Jun (rat) ▲
Orthologous residues
Jun (human): S73‑p, Jun (mouse): S73‑p, Jun (rat): S73‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioma, ovarian cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), OVCAR5 (ovarian), SNB-19 (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  CSM14.1 rat straital neuroprogenitor cell line
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
no change compared to control benzodiazepinones

T180-p - p38-alpha (rat) ▲
Orthologous residues
p38‑alpha (human): T180‑p, p38‑alpha iso2 (human): T180‑p, p38‑alpha (mouse): T180‑p, p38‑alpha (rat): T180‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioma, ovarian cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), OVCAR5 (ovarian), SNB-19 (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  CSM14.1 rat straital neuroprogenitor cell line
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
no change compared to control benzodiazepinones

Y182-p - p38-alpha (rat) ▲
Orthologous residues
p38‑alpha (human): Y182‑p, p38‑alpha iso2 (human): Y182‑p, p38‑alpha (mouse): Y182‑p, p38‑alpha (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioma, ovarian cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), OVCAR5 (ovarian), SNB-19 (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  CSM14.1 rat straital neuroprogenitor cell line
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
no change compared to control benzodiazepinones


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.